Financial Performance - The company's revenue for Q3 2023 reached ¥278,265,022.30, representing a 54.95% increase year-over-year[5] - Net profit attributable to shareholders was ¥50,215,465.97, up 94.01% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥48,268,848.87, reflecting a 97.76% increase year-over-year[5] - The company reported a significant increase in cash flow from operating activities, with a net amount of ¥215,850,869.32, up 451.56% year-to-date[5] - The company reported a total comprehensive income of CNY 151,348,408.60, compared to CNY 72,732,672.12 in the previous period, highlighting improved financial performance[16] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,665,468,277.92, a 3.48% increase from the end of the previous year[5] - Total assets as of September 30, 2023, amounted to CNY 2,665,468,277.92, an increase from CNY 2,575,733,822.26 at the beginning of the year[12] - Current assets decreased to CNY 1,078,659,822.13 from CNY 1,133,123,579.22, primarily due to a reduction in cash and accounts receivable[12] - Total liabilities decreased to CNY 691,946,321.50 from CNY 708,199,697.29, reflecting a reduction in current liabilities[13] - Non-current assets increased to CNY 1,586,808,455.79 from CNY 1,442,610,243.04, driven by growth in fixed assets[13] Shareholder Information - The company has no preferred shareholders as of the reporting date[11] - The top shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares, totaling 147,987,000 shares[10] Earnings and Profitability - The company's basic earnings per share rose to ¥0.2214, a 94.05% increase from the same period last year[5] - Operating profit for the period was CNY 178,634,888, up 110.7% from CNY 84,576,313 in the previous period[16] - Net profit attributable to shareholders of the parent company was CNY 151,241,017, representing a 107.5% increase from CNY 72,769,914 in the previous period[16] - Basic and diluted earnings per share increased to CNY 0.6668, compared to CNY 0.3209 in the previous period[17] Research and Development - Research and development expenses for the period were ¥50,435,388.95, an increase of 78.37% compared to the previous year[8] - Research and development expenses increased to CNY 50,435,388.95, up from CNY 28,275,340.82 in the previous period, indicating a focus on innovation[15] Cash Flow - The net cash flow from investment activities was -225,060,828.76 CNY, compared to -181,594,782.57 CNY in the previous period, indicating an increase in cash outflow[18] - The cash inflow from financing activities totaled 123,391,065.12 CNY, down from 424,793,884.69 CNY in the previous period[18] - The net cash flow from financing activities was -93,042,457.83 CNY, a significant decrease from 394,389,158.72 CNY in the previous period[18] - The total cash and cash equivalents at the end of the period were 192,239,644.28 CNY, down from 483,500,609.89 CNY at the end of the previous period[18] - The company reported a net decrease in cash and cash equivalents of -102,252,417.27 CNY for the quarter[18] Inventory and Accounts Receivable - Inventory increased to CNY 687,633,973.81, up from CNY 605,510,451.16, indicating a 13.5% rise[12] - Accounts receivable decreased to CNY 64,776,677.66 from CNY 102,844,379.69, a reduction of about 37%[12] Audit Information - The company did not undergo an audit for the third quarter report[19]

证券代码:002880 证券简称:卫光生物 公告编号:2023-048 深圳市卫光生物制品股份有限公司 2023 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司） 2023 年半年度权益分派方案 已经 2023 年 9 月 15 日召开的 2023 年第三次临时股东大会审议通过，现将权益分派事 宜公告如下： 一、股东大会审议通过利润分配方案情况 1.公司 2023 年半年度利润分配方案为：以公司截至 2023 年 6 月 30 日的总股本 226,800,000 股为基数，每 10 股派发现金红利 2 元（含税），拟派发现金红利总额为 45,360,000 元，不送红股，不以公积金转增股本。 三、股权登记日与除权除息日 本次权益分派股权登记日为：2023 年 10 月 30 日； 除权除息日为：2023 年 10 月 31 日。 四、权益分派对象 本次分派对象为：截止 2023 年 10 月 30 日下午深圳证券交易所收市后，在中国证 券登记结算有限责任公司深圳分公司（以下简称中国结算深圳 ...

证券代码:002880 证券简称:卫光生物 公告编号:2023-047 深圳市卫光生物制品股份有限公司 2023年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1.本次股东大会召开期间无否决议案的情况； 2.本次股东大会未涉及变更以往股东大会已通过议案的情况。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议：2023 年 9 月 15 日 15:00。 （二）会议出席情况 出席会议总体情况：公司总股本为 226,800,000 股，通过现场和网络参加本 次会议的股东及股东代表共计15人，代表公司有表决权的股份为166,227,900股， 占公司有表决权股份总数的 73.2927%。其中，中小投资者共计 13 人，代表公司 有表决权的股份 1,797,900 股，占公司股份总数的 0.7927%。 现场会议出席情况：参加本次股东大会现场会议的股东及股东代理人共 3 人， 代表有表决权的公司股份数合计为 164,430,100 股，占公司有表决权股份总数的 72.5000%。 网络投票情况： ...

上海市锦天城（深圳）律师事务所 法律意见书 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2023 年第三次临时股东大会的 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 一、本次股东大会召集、召开的程序 经本所律师验证： 2023 年第三次临时股东大会的 法律意见书 致：深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受深圳市卫光生 物制品股份有限公司（以下简称"公司"）的委托，指派律师出席公司 2023 年第 三次临时股东大会（以下简称"本次股东大会"），并根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）等法 律、法规和规范性文件以及现行有效的《深圳市卫光生物制品股份有限公司章程》 （以下简称"《公司章程》"）的相关规定 ...

Financial Performance - The company's operating revenue for the first half of 2023 was RMB 457,166,651.70, representing a 97.18% increase compared to RMB 231,846,735.14 in the same period last year[20]. - The net profit attributable to shareholders was RMB 101,025,551.22, up 115.47% from RMB 46,886,654.69 year-on-year[20]. - The net cash flow from operating activities reached RMB 222,999,664.96, a significant increase of 1,650.61% compared to a negative cash flow of RMB 14,381,375.99 in the previous year[20]. - Basic earnings per share rose to RMB 0.4454, reflecting a 115.48% increase from RMB 0.2067 in the same period last year[20]. - Total assets at the end of the reporting period were RMB 2,656,596,662.42, a 3.14% increase from RMB 2,575,733,822.26 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 5.49% to RMB 1,941,834,617.34 from RMB 1,840,809,066.12 at the end of the previous year[20]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, which was RMB 99,477,403.38, up 131.81% from RMB 42,913,847.59 in the previous year[20]. - The company achieved a revenue of CNY 457.17 million, representing a year-on-year growth of 97.18%[36]. - The net profit attributable to shareholders reached CNY 101.03 million, with a year-on-year increase of 115.47%[36]. Operational Highlights - The company operates 9 single-source plasma stations, with the average plasma collection volume leading the industry[29]. - The Pingguo plasma station has maintained steady growth in plasma collection volume, ranking among the top in the industry[29]. - The company has established a cooperation agreement with the Belarusian government for the production licensing and technology transfer of human albumin and intravenous immunoglobulin (pH4)[29]. - The company is the first in China to achieve technology output in the blood product sector, aiming to expand its international market presence[29]. - The company is actively expanding its product line to include vaccines and gene-engineered products, in addition to its core blood products[31]. - The company has signed a cooperation agreement with China National Pharmaceutical Group, which will change its actual controller and enhance resource integration in the industry[30]. - The company has implemented lean management practices to improve production efficiency and product quality, maintaining a leading position in product yield within the industry[38]. - The company is focusing on enhancing its marketing strategies to increase market recognition and trust in its products[36]. Research and Development - Research and development expenses amounted to ¥18,783,841.17, reflecting a 30.26% increase from ¥14,420,128.88 in the previous year, indicating a commitment to enhancing R&D capabilities[44]. - The company has obtained a total of 48 national authorized patents, including 19 invention patents and 29 utility model patents, showcasing its strong focus on innovation[39]. - The company has established eight major research and innovation platforms, enhancing its technological capabilities and fostering collaboration with renowned research institutions[42]. - The company is focusing on research and development to innovate and enhance its product offerings in the biopharmaceutical sector[164]. Market and Competition - The company anticipates increased market competition in the industry, particularly for products like human fibrinogen and recombinant factor VIII[70]. - Strategies to combat market competition include optimizing marketing strategies, exploring international markets, and enhancing brand recognition[70]. - The company plans to expand its market presence and invest in new product development to drive future growth[161]. Environmental and Social Responsibility - The company has a wastewater treatment facility with a design capacity of 300 tons per day, ensuring compliance with local environmental standards[85]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[89]. - The company has implemented an emergency response plan for environmental incidents, enhancing its preparedness for potential environmental emergencies[86]. - The company has actively participated in social responsibility initiatives, balancing economic, environmental, and social interests[92]. - The company has increased employee awareness of environmental protection through its low-carbon and energy-saving initiatives[88]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 9,802[124]. - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of the shares, totaling 147,987,000 shares[124]. - The total number of unrestricted shares is 226,800,000, representing 100% of the total shares[122]. - The company declared a cash dividend of 2.00 yuan per 10 shares, totaling 45,360,000 yuan, which represents 100% of the profit distribution[75][76]. Risks and Challenges - The company faces risks related to insufficient raw material supply, particularly human plasma, which is scarce and subject to regulatory approval for new collection stations[66]. - To mitigate raw material supply risks, the company plans to enhance existing plasma collection capabilities, recruit new donors, and improve collection rates[67]. - The company acknowledges risks in new product development due to various factors including technology, clinical outcomes, and regulatory approvals, which may lead to delays or failures[68]. - Potential product safety risks exist despite advanced collection and production technologies, necessitating stringent quality management and process optimization[69]. Financial Position - The company's total liabilities were CNY 688.18 million, a slight decrease from CNY 708.20 million at the beginning of the year, indicating a reduction of approximately 2.0%[140]. - The total equity attributable to shareholders reached CNY 1.94 billion, an increase from CNY 1.84 billion at the beginning of the year, representing a growth of about 5.6%[140]. - Cash and cash equivalents stood at CNY 291.90 million as of June 30, 2023, compared to CNY 214.36 million at the beginning of the year, reflecting an increase of approximately 36.1%[142]. - The company reported a credit impairment loss of CNY 3,415,276.86, which is an increase from CNY 2,425,762.20 in the same period of 2022[151]. Accounting and Compliance - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status[177]. - The company includes all subsidiaries in its consolidated financial statements, ensuring uniform accounting policies across entities[184]. - The company recognizes goodwill in business combinations when the purchase cost exceeds the fair value of identifiable net assets acquired[183].

第三届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第十九次 会议于2023年8月23日在深圳市光明区光侨大道3402号公司办公楼四楼以现场结 合通讯方式召开。本次会议应参加董事8名，实际参加董事8名，公司监事及高级 管理人员列席了会议。本次会议由董事长张战先生主持，会议的召集、召开和表 决程序符合《公司法》等有关法律、法规及《公司章程》的规定。 二、董事会会议审议情况 证券代码:002880 证券简称:卫光生物 公告编号:2023-042 深圳市卫光生物制品股份有限公司 表决结果：同意票8票，反对票0票，弃权票0票。 公司独立董事对本议案发表了独立意见，具体内容详见同日在巨潮资讯网 (www.cninfo.com.cn)披露的相关公告。 本议案尚需提交股东大会审议。 3. 审议通过了《关于召开2023年第三次临时股东大会的议案》。 董事会经审议同意于 2023 年 9 月 15 日召开 2023 年第三次临时股东大会。 具体内容详见公司同日在指定信 ...

二、监事会会议审议情况 会议经逐项审议，书面表决，审议通过了如下议案： 1.审议通过了《关于<2023年半年度报告>及其摘要的议案》； 证券代码:002880 证券简称:卫光生物 公告编号:2023-043 深圳市卫光生物制品股份有限公司 第三届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届监事会第十五次 会议于 2023 年 8 月 23 日在深圳市光明区光明街道光侨大道 3402 号公司办公楼 4 楼以现场方式召开，会议应出席监事 3 名，实际出席监事 3 名。本次会议由监 事会主席邬玉生先生主持，会议的召集、召开和表决程序符合《公司法》和《公 司章程》的规定。 三、备查文件 第三届监事会第十五次会议决议 特此公告。 深圳市卫光生物制品股份有限公司监事会 2023年8月25日 经审核，监事会认为董事会编制和审议《2023年半年度报告》及其摘要的程 序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在虚假记载、 ...

深圳市卫光生物制品股份有限公司（以下简称公司）于 2023 年 8 月 23 日召 开第三届董事会第十九次会议、第三届监事会第十五次会议，审议通过了《关于 2023 年半年度利润分配预案的议案》，上述议案尚需提交公司 2023 年第三次临 时股东大会审议。现将该预案有关情况公告如下： 一、2023 年半年度利润分配预案 为积极回报全体股东，并结合公司实际经营情况，公司拟定 2023 年半年度 利润分配预案为：以公司截至 2023 年 6 月 30 日的总股本 226,800,000 股为基数， 每 10 股派发现金红利 2 元（含税），拟派发现金红利总额为 45,360,000 元，不 送红股，不以公积金转增股本。若在分配方案实施前公司总股本发生变化，将按 照分派总额不变的原则相应调整分配比例。 公司上述分配预案符合《公司法》《上市公司监管指引第 3 号——上市公司 现金分红》及《公司章程》等的规定。 二、本次利润分配预案的决策程序 公司 2023 年半年度利润分配预案已经公司第三届董事会第十九次会议及第 三届监事会第十五次会议审议通过，独立董事发表了同意的独立意见。具体情况 详见公司于同日刊登在指定信息披露 ...

企业负责人：张战 主管会计工作负责人：岳章标 会计机构负责人：黄悝 | 其他关联人 | | | | | | --- | --- | --- | --- | --- | | 及其附属企 | | | | | | 业 | | | | | | 小计 | | | | | | 总计 | 0.00 0.00 | 0.00 | 0.00 | 0.00 | 深圳市卫光生物制品股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资 | 资金占用 | 占用方与上 | 上市公司核算 | 2023 年期初 | 2023 年 1-6 占用累计发生 | 月 | 2023 年 | 1-6 | 2023 年 | 1-6 | 2023 年 1- | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 金占用 | | 市公司的关 | | 占用资金余 | | | 月占用资金的 | | 月偿还累计 | | 6 月期末占 | 占用形成原因 | 占用性质 | | | 方名称 | 联关系 ...

深圳市卫光生物制品股份有限公司 独立董事对第三届董事会第十九次会议相关事项的 我们认为公司 2023 年半年度利润分配预案综合考虑了公司实际经营情况和 股东合理回报，符合《公司章程》等的相关规定，有利于维护全体股东的利益， 不存在侵害中小投资者利益的情形。我们同意公司董事会拟定的 2023 年半年度 利润分配预案，并同意将上述预案提交公司 2023 年第三次临时股东大会审议。 独立董事：汪新民、杨新发、王艳梅 2023 年 8 月 23 日 独立意见 根据《上市公司独立董事规则》以及《深圳市卫光生物制品股份有限公司章 程》等的规定，作为深圳市卫光生物制品股份有限公司（以下简称公司）的独立 董事，我们认真审阅了该等事项相关资料，并且与公司相关人员进行了有效沟通， 对公司第三届董事会第十九次会议相关事项发表独立意见如下： 关于 2023 年半年度利润分配预案的独立意见 ...